Ciro Reyes, MD
General Practice · Miami, FLNPI 1952441651
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $8,041 of the $8,651 with a category attached, or 93.0%. Every reported general payment came from a single manufacturer, Novo Nordisk AS. Among general practice clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 6 payments — averaging $1441.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$9K
Across 992 payments — averaging $692.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$687K
What the payments were for
- Travel & lodging$8,04193%
- Food & beverage$6107%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 6 | $8,651 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$7,749
How this compares
$8,651 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 17 | $19,702 |
| OzempicSemaglutide | 14 | $11,004 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,377 |
| Lidocaine | 15 | $3,151 |
| Glipizide | 23 | $811 |
| Gabapentin | 34 | $704 |
| SynthroidLevothyroxine Sodium | 24 | $568 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $513 |
| Atorvastatin Calcium | 65 | $328 |
| Metoprolol Succinate | 29 | $325 |
| Omeprazole | 35 | $293 |
| Enalapril Maleate | 16 | $267 |
| Alprazolam | 28 | $221 |
| Atenolol | 11 | $215 |
| Pantoprazole Sodium | 13 | $214 |
Paid to pharmacies, not to this prescriber.
Other general practice in Miami
- Idalia AcostaMiami$99K
- Eddie GomezMiami$59K
- Aladino ValienteMiami$24K
- Viviana WaichMiami$20K
- Libia RiosMiami$15K
- Jose CardonaMiami$15K
- Rosa HuguetMiami$15K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.